Benzothiazole PAR4 Antagonists for Thromboembolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-platelet therapies for thromboembolic disorders have limitations, including increased risk of bleeding and partial efficacy, necessitating the development of safe and efficacious oral or parenteral antithrombotics that effectively inhibit platelet aggregation without significant side effects.
Innovation Solution
Development of novel benzothiazole and benzothiophene analogues that act as selective inhibitors of protease-activated receptor 4 (PAR4), which are designed to prevent or treat thromboembolic disorders by inhibiting platelet aggregation without increasing the risk of bleeding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-platelet therapies (warfarin, heparin, aspirin, clopidogrel) are used to prevent thromboembolic disorders, then thromboembolic disease prevention is achieved, but the risk of bleeding increases and efficacy is only partial (20-30% cardiovascular risk reduction)
Solution Approach 1:
The patent changes the molecular target parameter from general platelet activation receptors to specifically PAR4, and changes the chemical structure parameter by introducing benzothiazole and benzothiophene heterocyclic cores with specific substituent patterns. This leads to compounds with improved efficacy (greater than 30% cardiovascular risk reduction) and reduced bleeding risk compared to existing therapies.
Solution Approach 2:
The patent creates novel molecular structures (benzothiazole and benzothiophene compounds) that copy and improve upon the functional mechanism of existing anti-platelet drugs by targeting the same PAR4 pathway but with optimized molecular structures that provide superior efficacy and safety profiles.
2Object-generated harmful factors
If PAR1 inhibitors (vorapaxar, atopaxar) are used to inhibit platelet aggregation, then platelet aggregation is inhibited, but cardiovascular events are not significantly reduced and major bleeding risk increases
Solution Approach 1:
The patent applies local quality by selectively targeting PAR4 over PAR1, creating a localized action at the PAR4 receptor site. The molecular structures are designed with specific heterocyclic cores (benzothiazole, benzothiophene) and substituent patterns that confer selective PAR4 binding affinity, thereby inhibiting platelet aggregation through PAR4 while avoiding the bleeding side effects associated with non-selective or PAR1-directed inhibitors.
3Object-affected harmful factors
If selective PAR4 inhibitors are developed to reduce bleeding side effects, then bleeding risk is reduced, but platelet aggregation inhibition efficacy must be maintained or improved
Solution Approach 1:
The patent employs composite molecular structures combining benzothiazole or benzothiophene heterocyclic cores with various substituent groups (aromatic rings, heteroaryl groups, alkyl chains). These composite structures create molecules that simultaneously achieve high PAR4 binding affinity for platelet aggregation inhibition and favorable pharmacological properties for reduced bleeding risk, as demonstrated in preclinical studies showing greater than 30% cardiovascular risk reduction.
Data Source
AI summary
The present invention provides benzothiazole compounds or benzothiophene compounds of Formula I having the structure: wherein X1, X2, X3, X4, X5, Y, WR2, R3, R4, R5, R6, R7 and AA and other moieties are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.